UBE2D3 and familial pancreatic carcinoma: In the present study, we demonstrated the clinical relevance of UbcH5c with pancreatic cancer and identified a potent UbcH5c inhibitor DHPO, which showed anticancer efficacy in pancreatic cancer cell models in vitro and in vivo via inhibiting the NF-κB signaling pathway.